Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 199

1.
2.

Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs.

Lee YH, Bae SC, Song GG.

Int J Rheum Dis. 2013 Oct;16(5):527-31. doi: 10.1111/1756-185X.12154. Review.

PMID:
24164839
3.

No detection of occult HBV-DNA in patients with various rheumatic diseases treated with anti-TNF agents: a two-year prospective study.

Giardina AR, Ferraro D, Ciccia F, Ferrante A, Di Stefano R, Craxì A, Triolo G.

Clin Exp Rheumatol. 2013 Jan-Feb;31(1):25-30. Epub 2012 Aug 30.

PMID:
22935442
4.

Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.

Lan JL, Chen YM, Hsieh TY, Chen YH, Hsieh CW, Chen DY, Yang SS.

Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.

PMID:
21719446
5.

Lack of hepatitis B virus reactivation after anti-tumour necrosis factor treatment in potential occult carriers with chronic inflammatory arthropathies.

Biondo MI, Germano V, Pietrosanti M, Canzoni M, Marignani M, Stroffolini T, Salemi S, D'Amelio R.

Eur J Intern Med. 2014 Jun;25(5):482-4. doi: 10.1016/j.ejim.2013.11.014. Epub 2014 Feb 2.

PMID:
24495663
6.

Hepatitis B virus reactivation associated with antirheumatic therapy: Risk and prophylaxis recommendations.

Mori S, Fujiyama S.

World J Gastroenterol. 2015 Sep 28;21(36):10274-89. doi: 10.3748/wjg.v21.i36.10274. Review.

7.

Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.

Giaccone L, Festuccia M, Marengo A, Resta I, Sorasio R, Pittaluga F, Fiore F, Boccadoro M, Rizzetto M, Bruno B, Marzano A.

Biol Blood Marrow Transplant. 2010 Jun;16(6):809-17. doi: 10.1016/j.bbmt.2009.12.533. Epub 2010 Jan 7.

8.

Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.

Chung SJ, Kim JK, Park MC, Park YB, Lee SK.

J Rheumatol. 2009 Nov;36(11):2416-20. doi: 10.3899/jrheum.081324. Epub 2009 Oct 1. Erratum in: J Rheumatol. 2010 Jan;37(1):216.

PMID:
19797507
9.

Safety of tumor necrosis factor alpha blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti-hepatitis B core antigen positive) with rheumatic diseases.

Caporali R, Bobbio-Pallavicini F, Atzeni F, Sakellariou G, Caprioli M, Montecucco C, Sarzi-Puttini P.

Arthritis Care Res (Hoboken). 2010 Jun;62(6):749-54. doi: 10.1002/acr.20130.

10.

Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.

Papadopoulos N, Deutsch M, Manolakopoulos S, Bitsi C, Michalakeas H, Poulakidas H, Tsironi E, Giannouli S, Papatheodoridis GV, Koskinas J, Pectasides D.

Eur J Gastroenterol Hepatol. 2017 Jan;29(1):56-60.

PMID:
27669175
11.

Fatal reactivation of hepatitis B virus in a patient who was hepatitis B surface antigen negative and core antibody positive before receiving chemotherapy for non-Hodgkin lymphoma.

Wu JM, Huang YH, Lee PC, Lin HC, Lee SD.

J Clin Gastroenterol. 2009 May-Jun;43(5):496-8. doi: 10.1097/MCG.0b013e3181945942.

PMID:
19247200
12.

Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature.

Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, Airò P.

J Rheumatol. 2009 Jun;36(6):1188-94. doi: 10.3899/jrheum.081246. Epub 2009 May 15. Review.

PMID:
19447932
13.

Prospective study of HBV reactivation risk in rheumatoid arthritis patients who received conventional disease-modifying antirheumatic drugs.

Tan J, Zhou J, Zhao P, Wei J.

Clin Rheumatol. 2012 Aug;31(8):1169-75. doi: 10.1007/s10067-012-1988-2. Epub 2012 Apr 28.

PMID:
22544263
14.

Reactivation of hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs.

Nakamura J, Nagashima T, Nagatani K, Yoshio T, Iwamoto M, Minota S.

Int J Rheum Dis. 2016 May;19(5):470-5. doi: 10.1111/1756-185X.12359. Epub 2014 Apr 4.

PMID:
24698305
15.

A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy.

Notarnicola A, Iannone F, Lopalco G, Covelli M, Lapadula G.

Reumatismo. 2014 Mar 17;65(6):298-301. doi: 10.4081/reumatismo.2013.727.

16.

Reactivation of occult hepatitis B virus infection under treatment with abatacept: a case report.

Talotta R, Atzeni F, Sarzi Puttini P.

BMC Pharmacol Toxicol. 2016 Apr 21;17:17. doi: 10.1186/s40360-016-0060-2.

17.

Anti-tumor necrosis factor treatment in occult hepatitis B virus infection: a retrospective analysis of 62 patients with psoriatic disease.

Cassano N, Mastrandrea V, Principi M, Loconsole F, De Tullio N, Di Leo A, Vena GA.

J Biol Regul Homeost Agents. 2011 Apr-Jun;25(2):285-9.

PMID:
21880218
18.

The difficulties of managing severe hepatitis B virus reactivation.

Roche B, Samuel D.

Liver Int. 2011 Jan;31 Suppl 1:104-10. doi: 10.1111/j.1478-3231.2010.02396.x. Review.

PMID:
21205146
19.

Incidence and characteristics of HBV reactivation in hematological malignant patients in south Egypt.

Elkady A, Aboulfotuh S, Ali EM, Sayed D, Abdel-Aziz NM, Ali AM, Murakami S, Iijima S, Tanaka Y.

World J Gastroenterol. 2013 Oct 7;19(37):6214-20. doi: 10.3748/wjg.v19.i37.6214.

20.

Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.

Liu WP, Zheng W, Song YQ, Ping LY, Wang GQ, Zhu J.

World J Gastroenterol. 2014 May 7;20(17):5165-70. doi: 10.3748/wjg.v20.i17.5165.

Supplemental Content

Support Center